Eam Investors, LLC Catalyst Pharmaceuticals, Inc. Transaction History

Eam Investors, LLC

$581 Million
Q3 2024

A detailed history of Eam Investors, LLC transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Eam Investors, LLC holds 161,249 shares of CPRX stock, worth $3.49 Million. This represents 0.55% of its overall portfolio holdings.

Number of Shares

161,249

Holding current value

$3.49 Million

% of portfolio

0.55%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$15.19 - $21.35 $2.45 Million - $3.44 Million	161,249 New	161,249 $3.21 Million
Q4 2022 Feb 14, 2023	SELL	$12.25 - $19.5 $410,840 - $653,991	-33,538 Reduced 18.45%	148,261 $2.76 Million
Q3 2022 Nov 14, 2022	SELL	$7.06 - $15.52 $1.12 Million - $2.45 Million	-158,143 Reduced 46.52%	181,799 $2.33 Million
Q2 2022 Aug 12, 2022	SELL	$6.23 - $8.57 $158,696 - $218,303	-25,473 Reduced 6.97%	339,942 $2.38 Million
Q1 2022 May 13, 2022	BUY	$5.31 - $8.31 $670,886 - $1.05 Million	126,344 Added 52.85%	365,415 $3.03 Million
Q4 2021 Feb 11, 2022	BUY	$5.21 - $7.45 $1.25 Million - $1.78 Million	239,071 New	239,071 $1.62 Million
Q2 2019 Aug 14, 2019	SELL	$2.7 - $6.11 $1.35 Million - $3.05 Million	-498,844 Closed	0 $0
Q1 2019 May 13, 2019	BUY	$2.11 - $5.33 $1.05 Million - $2.66 Million	498,844 New	498,844 $2.54 Million
Q1 2018 May 14, 2018	SELL	$2.39 - $4.01 $1.89 Million - $3.17 Million	-790,872 Closed	0 $0
Q4 2017 May 21, 2018	SELL	$2.51 - $4.4 $631,633 - $1.11 Million	-251,647 Reduced 24.14%	790,872 $3.09 Million
Q4 2017 Feb 12, 2018	BUY	$2.51 - $4.4 $2.62 Million - $4.59 Million	1,042,519	1,042,519 $4.08 Million

Others Institutions Holding CPRX

# of Institutions

327

Shares Held

94.6M

Call Options Held

19.1K

Put Options Held

51.1K

View Full List

About CATALYST PHARMACEUTICALS, INC.

Ticker CPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,820,000
Market Cap $2.23B
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...

More about CPRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Eam Investors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Eam Investors, LLC with notifications on news.

Account

Eam Investors, LLC Catalyst Pharmaceuticals, Inc. Transaction History